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Abstract: Cryptophycins are potent tubulin polymerization inhibitors with picomolar
antiproliferative potency in vitro and activity against multidrug-resistant (MDR) cancer cells. Because
of neurotoxic side effects and limited efficacy in vivo, cryptophycin-52 failed as a clinical candidate
in cancer treatment. However, this class of compounds has emerged as attractive payloads for
tumor-targeting applications. In this study, cryptophycin was conjugated to the cyclopeptide
c(RGDfK), targeting integrin αvβ3, across the protease-cleavable Val-Cit linker and two different
self-immolative spacers. Plasma metabolic stability studies in vitro showed that our selected payload
displays an improved stability compared to the parent compound, while the stability of the conjugates
is strongly influenced by the self-immolative moiety. Cathepsin B cleavage assays revealed that
modifications in the linker lead to different drug release profiles. Antiproliferative effects of
Arg-Gly-Asp (RGD)–cryptophycin conjugates were evaluated on M21 and M21-L human melanoma
cell lines. The low nanomolar in vitro activity of the novel conjugates was associated with inferior
selectivity for cell lines with different integrin αvβ3 expression levels. To elucidate the drug delivery
process, cryptophycin was replaced by an infrared dye and the obtained conjugates were studied by
confocal microscopy.
Keywords: antitumor agents; small molecule–drug conjugates; drug delivery; RGD peptides
1. Introduction
The selective delivery of cytotoxic drugs to tumors is a promising approach to overcome the
drawbacks of traditional chemotherapy, such as limited efficacy and increased systemic toxicity [1].
Several antibody–drug conjugates (ADCs) and small molecule–drug conjugates (SMDCs) have been
developed to increase the therapeutic index of cytotoxic agents by conjugating them to a delivery
vehicle (i.e., antibody or small molecule) specifically binding to its target antigen present on the tumor
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cell surface [2–4]. Many of them are at various stages of clinical and preclinical development, and four
ADCs (Adcetris®, Kadcyla®, Mylotarg®, and Besponsa®) have been approved for cancer treatment [5].
Despite the significant success of ADCs, several limitations, like an unfavorable pharmacokinetic profile
(low tissue diffusion and low tumor accumulation), immunogenicity, and high manufacturing costs,
still need to be addressed [6]. Due to their smaller size, SMDCs have emerged as good alternatives
for ADCs. In this case, the straightforward chemical synthesis and easier purification of SMDCs
significantly reduces the production costs and allows an extensive hit to lead optimization. Moreover,
SMDCs exhibit improved tumor penetration and do not trigger an immune response. However,
because of their faster plasma clearance that allows reduced off-target tissue exposure, more frequent
dosing may be required [7,8].
Cryptophycins are a family of 16-membered macrocyclic depsipeptides, first isolated from
cyanobacteria Nostoc sp. in 1990 [9]. This class of compounds is able to arrest the cell cycle in
the G2/M phase by inhibition of microtubule polymerization at substoichiometric concentrations and
by depolymerization of microtubules [10,11], resulting in picomolar antiproliferative potency in vitro.
Moreover, cryptophycins are poor substrates for P-glycoprotein (P-gp)-mediated transport, leading to
retained activity against multidrug-resistant (MDR) cells [12]. The synthetic analogue, cryptophycin-52
(LY355703, 2, Figure 1) was developed as a potential clinical candidate but failed to exhibit significant
response and showed unacceptable levels of neurotoxicity at the administered doses for the treatment
of non-small cell lung cancer and platinum-resistant ovarian cancer [13,14]. Further investigations
were not only focused on the development of functionalized cryptophycin analogues [15–17], but also
on the conjugation of cryptophycin to tumor-homing peptides [18,19] and antibodies [20–22].
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it failed in clinical phase III as anti-angiogenic agent for glioblastoma treatment [35]. Based on the 
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Among the various functionalized cryptophycin derivatives, the chlorohydrin analogue of
cryptophycin-52 (cryptophycin-55, 3, Figure 1) proved to be more active but less stable compared
to the parent compound, while the glycinate ester of the chlorohydrin (4, Figure 1) displays both
chemical stability and comparable or superior in vivo activity against solid tumors of mouse and
human origin [23]. The free amino group of the glycinate provides a suitable attachment site for
conjugation to delivery vehicles across a carbamate or amide bond formation. We have previously
reported the application of cryptophycin-55 glycinate (Cry-55gly) for the development of tumor
targeting ADCs [24] and SMDCs [25,26]. The conjugation of this payload to other targeting moieties is
of considerable interest.
Integrins, a family of 24 heterodimeric transmembrane glycoproteins composed of 18 different
α subunits and 8 β subunits, became widely studied targets in anticancer therapy due to their
involvement in many steps of tumor growth [27]. The integrin αvβ3 is highly abundant in several
human cancer cells (including melanoma, glioblastoma, prostate, pancreatic, breast cancer); it is
overexpressed on the endothelial cells of tumor neovasculature, and it is involved in cancer progression
and metastasis [28–30]. Integrin αvβ3 recognizes its endogenous ligands by the tripeptide Arg-Gly-Asp
(RGD) sequence [31]. Consequently, a large number of linear and cyclic RGD containing peptides and
peptidomimetics have been developed with high binding affinity to the receptor [32–34]. Cilengitide,
c(RGDf(NMe)V), evolved as a highly active and selective ligand from structure–activity relationship
studies utilizing the concept of conformation-dependent recognition. However, it failed in clinical
phase III as anti-angiogenic agent for glioblastoma treatment [35]. Based on the fact that replacement
of Val to Lys does not affect receptor binding and Lys can be used as a chemical handle to attach
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different entities, the functionalized cyclic pentapeptide c(RGDfK) is broadly applied as carrier for
imaging [36,37] and pharmacodelivery [38–41] applications.
We have previously prepared an azido-functionalized cryptophycin derivative that was
conjugated to a modified c(RGDfK) peptide across a non-cleavable triazole ring. The resulting conjugate
showed an inferior cytotoxicity compared to the parent drug due to the stability of the linkage between
the cytotoxin and the RGD ligand which did not allow the release of the free drug. Moreover, we have
reported that a fluorescent cryptophycin–RGD conjugate undergoes fast endocytosis and shows
colocalization with the lysosomes of human tumor cells [18]. For these reasons, conjugates with
lysosomally cleavable linkers represent an excellent potential to ensure increased antitumor activity.
2. Materials and Methods
2.1. Synthesis of Cryptophycin Conjugates
Synthesis of Alkynyl-PEG5-Val-Cit-PABC-Cry-55gly (7): Cryptophycin-55 glycinate (Cry-55gly,
4) was synthesized as previously described [25]. Here, 4 (5 mg, 6.5 µmol, 1 eq) and 5 (16 mg,
19.2 µmol, 3 eq) were dissolved in anhydrous N,N-dimethylformamide (DMF) (500 µL) under argon.
N,N-diisopropylethylamine (DIPEA) (5 µL, 29.2 µmol, 4.5 eq) was added and the mixture was stirred
for 4 h at room temperature (RT), followed by reversed-phase high-performance liquid chromatography
(RP-HPLC) purification (method M2/b, see Supplementary Material) to yield 7 as a colorless solid
(6.0 mg, 63%). Liquid Chromatography-Mass Spectrometry (LC-MS): tR = 10.28 min, >99% purity
(λ = 220 nm), m/z calcd for [C71H100Cl2N8O20]2+: 727.32 [M + 2H]2+, found: 727.34.
Synthesis of Alkynyl-PEG5-Val-Cit-Gly-Pro-Cry-55gly (8): Here, 4 (4 mg, 5.25 µmol, 1 eq),
6 (16 mg, 21 µmol, 4 eq), benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
(PyBOP) (11 mg, 21 µmol, 4 eq), and N-hydroxybenzotriazole (HOBt) (4 mg, 24 µmol, 4.5 eq) were
dissolved in anhydrous DMF (700 µL) under argon. DIPEA (4 µL, 24 µmol, 4.5 eq) was added and
the mixture was stirred for 4 h at RT, followed by RP-HPLC purification (method M2/b) to yield 8
as a colorless solid (6.0 mg, 78%). LC-MS: tR = 10.05 min, >99% purity (λ = 220 nm), m/z calcd for
[C70H102Cl2N9O20]+: 1458.66 [M + H]+, found: 1458.69; m/z calcd for [C70H103Cl2 N9O20]2+: 729.83
[M + 2H]2+, found: 729.85.
Synthesis of c(RGDfK)-PEG5-Val-Cit-PABC-Cry-55gly (10): Here, 7 (3.5 mg, 2.4 µmol, 1 eq),
9 (1.9 mg, 2.6 µmol, 1.1 eq), CuSO4·5H2O (0.3 mg, 1.2 µmol, 0.5 eq), and sodium ascorbate (0.29 mg,
1.4 µmol, 0.6 eq) were dissolved in DMF/H2O (1:1, 200 µL, degassed) and stirred for 24 h at 35 ◦C,
followed by RP-HPLC purification (method M2/b) to yield 10 as a colorless solid (3.3 mg, 64%).
LC-MS: tR = 7.77 min, >99% purity (λ = 220 nm), m/z calcd for [C101H144Cl2N20O28]2+: 1077.49
[M + 2H]2+, found: 1077.52; m/z calcd for [C101H145Cl2N20O28]3+: 718.66 [M + 3H]3+, found:
718.68. High Resolution Mass Spectrometry, Electrospray Ionization Mass Spectrometry (HRMS
(ESI-MS)): m/z calcd for [C101H144Cl2N20O28]2+: 1077.4913 [M + 2H]2+, found: 1077.4867; m/z calcd
for [C101H145Cl2N20O28]3+: 718.6633 [M + 3H]3+, found: 718.6595.
Synthesis of c(RGDfK)-PEG5-Val-Cit-Gly-Pro-Cry-55gly (11): Here, 8 (3.5 mg, 2.4 µmol, 1 eq),
9 (1.8 mg, 2.6 µmol, 1.1 eq), CuSO4·5H2O (0.3 mg, 1.2 µmol, 0.5 eq), and sodium ascorbate (0.29 mg,
1.4 µmol, 0.6 eq) were dissolved in DMF/H2O (1:1, 200 µL, degassed) and stirred for 24 h at 35 ◦C,
followed by RP-HPLC purification (method M2/b) to yield 11 as a colorless solid (2.80 mg, 54%).
LC-MS: tR = 7.31 min, >99% purity (λ = 220 nm), m/z calcd for [C100H147Cl2N21O28]2+: 1080.00 [M +
2H]2+, found: 1080.02; m/z calcd for [C100H148Cl2N21O28]3+: 720.34 [M + 3H]3+, found: 720.34; HRMS
(ESI-MS): m/z calcd for [C100H147Cl2N21O28]2+: 1080.0045 [M + 2H]2+, found: 1080.0126; m/z calcd
for [C100H148Cl2N21O28]3+: 720.3388 [M + 3H]3+, found: 720.3428.
2.2. Integrin Binding Assay
An ELISA-like assay using isolated integrins was performed to determine binding affinity [34].
Cilengitide (αvβ3: IC50 = 0.54 nM) was used as internal reference. All wells of flat-bottom 96-well
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Immuno Plates (BRAND GmbH & Co. KG, Wertheim, Germany) were coated overnight at 4 ◦C with
100 µL human vitronectin solution (1.0 µg/mL, #2349-VN-100, R&D Systems, Minneapolis, MI, USA)
in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). Each well was then washed with
phosphate-buffered saline/Tween20 (PBS-T-buffer, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4, 0.01% Tween20, pH 7.4; 3 × 200 µL) and blocked for 1 h at room temperature with
TS-B-buffer (Tris-saline/bovine serum albumin (BSA) buffer, 150 µL/well, 20 mM Tris-HCl, 150 mM
NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, pH 7.5, 1% BSA). A dilution series of the compound
and internal standard were prepared in TS-B-buffer. After washing the assay plate with PBS-T
(3 × 200 µL), 50 µL of the dilution series were transferred to each well, for negative control 100 µL
TS-B-buffer and for positive control 50 µL TS-B-buffer were used. Then, 50 µL of human αvβ3 integrin
(2.0 µg/mL, #3050-AV-050, R&D) in TS-B-buffer were transferred to wells (except wells containing
the negative control) and incubated for 1 h at RT. After washing the plates (3 × 200 µL) with PBS-T
buffer, 100 µL primary antibody mouse anti-human CD51/61 (2.0 µg/mL, #555504, BD Biosciences,
San Jose, CA, USA) were added to all wells and incubated for 1 h at RT. The plate was washed
(3 × 200 µL) with PBS-T buffer and 100 µL of secondary, peroxidase linked antibody (anti-mouse
IgG-POD goat, 1.0 µg/mL, #A441, Sigma Aldrich, St. Louis, MO, USA) were added to all wells and
incubated for 1 h at RT. The plate was washed (3 × 200 µL) with PBS-T buffer and 50 µL SeramunBlau
(SeramunBlau fast S-001-1-TMB, Seramun Diagnostica GmbH, Heidesee, Germany) were added to
all wells. The development was stopped with 3 M H2SO4 (50 µL/well) when a blue color gradient
was visible (∼1 min). The absorbance was measured with a plate reader at 450 nM (Tecan, Infinite
M200, Zürich, Switzerland). The resulting curves were analyzed with OriginPro 2017G (OriginLab
Corporation, Northampton, MA, USA) with the inflection point describing the IC50 value. Each
compound was tested twice in triplicates and referenced to the internal standard.
2.3. Plasma Metabolic Stability Assay
The sample preparation and the metabolic analysis of the conjugates was carried out similarly
to a previously described method [42]. In a 96-well plate, the stock solutions (3 mM in dimethyl
sulfoxide (DMSO)) of the conjugates and the control compound were diluted with 250 µL of plasma
(pooled heparinized mouse ICR/CD1 M plasma #08 or human plasma #MPLLIHP-M, #BHR1003077,
BioreclamationIVT, Westbury, NY, USA) to give a 3-µM concentration and incubated at 37 ◦C. At each
sampling time an aliquot of 30 µL was transferred into a 96-deep-well plate and the reaction was
stopped with 120 µL of acetonitrile (ACN) containing 0.1% HCOOH and 400 ng/mL of warfarin
as internal standard (IS). This mixture was centrifuged at 1100× g for 30 min at 4 ◦C and 50 µL of
supernatants were transferred into a clean 96-deep-well plate and diluted with 50 µL of 0.1% HCOOH
in water. Samples were stored at −80 ◦C prior to UPLC-HRMS analysis (see Supplementary Materials).
The stability was determined based on the disappearance of the test compound as a function of
incubation time, using area ratios (analyte peak area vs internal standard peak area). The elimination
constant k was calculated by plotting mean disappearance values on a semi-logarithmic scale and
fitting with a best fit linear regression using Microsoft Excel. The half-life (t1/2) expressed in hours
was determined using equation: t1/2 = ln2/(−k). Full metabolite analysis was done using Compound
DiscovererTM 2.1 (Thermo Fisher Scientific, Waltham, MA, USA) software.
2.4. Cathepsin B Cleavage Assay
L-cysteine (#C8152, Sigma Aldrich) was dissolved in acetate buffer/ethylenediaminetetraacetic
acid (EDTA) 1 mM pH 5.5 to get a solution with a final concentration of L-cysteine of 28 mM.
This solution was used to dilute an aliquot of cathepsin B (bovine spleen cathepsin B, #C6286, Sigma
Aldrich) to 1.11 U/mL. Sample containing cathepsin B was pre-incubated at 37 ◦C for 15 min and
then split into 45-µL aliquots in Eppendorf tubes, two replicates for each incubation time. Aliquots
of 5 µL of 50 µM solutions of the substrates prepared in MeOH/H2O (50/50) were added to each
tube, to get a final concentration of 5 µM. Tubes corresponding to t = 0 min contained 100 µL of 1%
Pharmaceutics 2019, 11, 151 5 of 15
HCOOH in MeOH and were put in an ice bath to stop the reaction. All the other tubes were incubated
at 37 ◦C in an oscillating thermostatic bath and reaction was stopped at the following incubation
times: 0.25, 0.5, 1, 2, 4, and 6 h, as described for t = 0 min samples. Samples were centrifuged for
10 min at 14,000 rpm at 4 ◦C and filtered with regenerated cellulose syringe filters prior to injection
in the HPLC-MS system (see Supplementary Materials). Control solutions of each compound (5 µM
in acetate buffer pH 5.5/EDTA 1 mM/L-cysteine 28 mM) were also prepared and incubated up to
6 h at 37 ◦C in the absence of the enzyme to check substrate stability at the incubation conditions.
Substrates and possible metabolites were quantified based on calibration curves prepared in acetate
buffer/EDTA/L-cysteine.
2.5. Degradation in Human Liver Lysosomal Homogenate
Pooled human liver lysosomes (#H0610.L) at 2.5 mg protein/mL, cathepsin B activity 96.5 ± 3.96
units/mg protein were purchased from Sekisui XenoTech (Kansas City, KS, USA).
Experiments were performed based on the method described previously [43], with some
modifications. Conjugates and control compound (Bz-FVR-p-nitroanilide, #B7632, Sigma Aldrich)
were diluted in 0.2 M citrate phosphate buffer, pH 5.5, containing 0.1% (v/v%) Triton X-100, 5 mM
reduced glutathione, 1 mM EDTA, and human liver lysosomes (1.5 mg protein/mL) to give a 3 µM
final concentration. At each time point (0, 0.5, 1, and 2 h) an aliquot of 30 µL was transferred into a
new 96-deep-well plate and the reaction was stopped with 120 µL of ACN containing 0.1% HCOOH
and 0.4 µg/mL of warfarin as internal standard (IS). At the end of the assay, the plate was centrifuged
at 1100× g for 30 min at 4 ◦C and 50 µL of the supernatant were transferred into a new 96-deep-well
plate. The sample was diluted with 50 µL of mixture of ACN/H2O/HCOOH = 20/80/0.1. Samples
were stored at −80 ◦C prior to UPLC-HRMS analysis (see Supplementary Materials).
2.6. In Vitro Cytotoxicity Assay
The human melanoma M21 and M21-L cells were kindly provided by Dr. David Cheresh and
The Scripps Research Institute (La Jolla, CA, USA). Cells were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% Penicillin/Streptomycin in a humidified
incubator at 37 ◦C and 5% CO2.
Cell viability was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Cells were plated at a density of 3000 cells/well (Nunc® MicroWell® flat-bottom 96-well
plate, Thermo Fisher Scientific) and incubated overnight to allow adherence. The following day, cells
were treated with serial dilutions of each compound or 0.1% DMSO as control. After 2 h of incubation,
cells were centrifuged at 1200 rpm for 5 min; supernatant containing the compounds was removed
and replaced with fresh medium. Cells were further incubated for 70 h as described above, and at the
end of treatment, 5 µL of MTT (5 mg/mL in deionized H2O, #M5655, Sigma Aldrich) were added to
each well and the cells incubated for another 2 h. Finally, 100 µL of lysis buffer (10% SDS, 10 mM HCl)
were added, and cells were placed in the incubator overnight for the formazan crystal solubilization.
Absorbance at 540 nm was measured using FLUOstar Omega (BMG Labtech, Ortenberg, Germany)
instrument and the growth inhibition ratio was calculated. Blank controls detecting cell-free media
absorbance were performed in parallel. Three experimental replicates were used. The half-maximal
inhibitory concentration values (IC50) were obtained from viability curves by fitting data to the
four-parameter logistic equation using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA).
The cell viability was expressed as percentage relative to the respective control conditions.
2.7. Flow Cytometry Analysis
The M21 and M21-L cells were plated at a density of 80,000 cells/mL/well in a 12-well plate
and incubated overnight at 37 ◦C. The next day, cells were incubated with LM142 mouse anti-human
integrin αV monoclonal antibody (#MAB1978, Merck Millipore, Merck KGaA, Darmstadt, Germany,
1:500 dilution) or with mouse anti-human CD51/CD61 (#555504, BD Biosciences, San Jose, CA, USA) at
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1 µg/mL for 15 min on ice. Subsequently, cells were washed with PBS and incubated with anti-mouse
IgG-Alexa Fluor 488 (#A-11029, Thermo Fisher Scientific) at 8.3 µg/mL for 15 min on ice. Finally, cells
were washed with PBS, and samples were acquired using BD FACSCaliburTM flow cytometer and
analyzed using FlowJo software v.10 (FlowJo LCC, Ashland, OR, USA). Anti-mouse IgG antibody was
used as the negative isotope control.
2.8. Confocal Microscopy
The real-time internalization of the fluorescently labeled compounds 15 and 16 was acquired
using a ZEISS LSM 880 confocal microscope (Carl Zeiss AG, Oberkochen, Germany) coupled with
an environmental chamber allowing a 37 ◦C, 5% CO2 atmosphere. The M21 and M21-L human
melanoma cells were grown overnight in eight-well chambered slides (Nunc® Lab-Tek®, Sigma
Aldrich) previously coated with poly-D-Lysine (10 µg/mL, Sigma Aldrich). The fluorescently labeled
conjugates were diluted in phenol red-free media to 1 µM (0.1% DMSO) and warmed up to 37 ◦C.
Picture acquisition was made using a 40× water immersion objective and started shortly after the
solutions were added to the cells, a frame was made every 30 s for a total of 60 frames. Brightfield was
used to distinguish the cell’s structures.
3. Results and Discussion
3.1. Design and Synthesis
The RGD–cryptophycin conjugates consist of the highly cytotoxic payload, cryptophycin-55
glycinate, and c(RGDfK) peptide connected through the protease-cleavable Val-Cit dipeptide linker,
which is extensively used in the ADC field [44]. This peptide-based linker displays an excellent balance
between high stability in circulation and rapid intracellular cleavage in the presence of lysosomal
proteases, mainly cathepsin B [45] and other cysteine cathepsins [46,47]. In order to achieve efficient
release of the cytotoxin in an active form, two different self-immolative spacers were inserted between
the drug and the cleavage site: the para-aminobenzyloxycarbonyl (PABC) spacer, which undergoes
1,6-elimination, or the Gly-Pro dipeptide unit, which was designed to decompose by diketopiperazine
formation [48,49]. A polyethylene glycol (PEG5) spacer was introduced between the integrin ligand
and the cleavage site to improve water solubility of the conjugate.
The RGD–cryptophycin conjugates 10 and 11 were prepared as shown in Scheme 1. For the
synthesis of cleavable linker 5, Val-Cit-PABOH was reacted with an alkyne-functionalized polyethylene
glycol spacer (19), followed by activation with bis(4-nitrophenyl) carbonate giving the desired
compound (Scheme S2). The cleavable linker 6 was synthetized by standard Fmoc/tBu solid-phase
peptide synthesis (SPPS) on 2-chlorotrityl chloride resin. The Val-Cit-Gly-Pro tetrapeptide was
elongated by the coupling of polyethylene glycol spacer (19) containing alkyne moiety on the
solid support. After cleavage from the resin and purification by preparative HPLC, the peptide
linker was obtained in good yield (32%) and excellent purity. Linkers 5 and 6 were conjugated to
cryptophycin-55 glycinate (4), which was synthetized as described previously [25], affording the
corresponding linker-drugs 7 and 8 in good yields (63–78%). The lysine residue of c(RGDfK) peptide
was modified with 3-azidopropanoic acid allowing the conjugation of the ligand 9 to the linker-drugs
7 and 8 by Cu(I) catalyzed azide–alkyne cycloaddition (CuAAC click reaction). The resulting final
conjugates 10 and 11 were purified by preparative HPLC and characterized by analytical HPLC
and HRMS.
3.2. Integrin Binding Affinity
To investigate how the conjugation affects the binding properties of our ligand, the binding
affinity of conjugates 10 and 11 was compared to those of free ligands (9 and cilengitide) using a
competitive ELISA-based assay (Figure 2A). Integrin binding assays were performed by incubation
of immobilized vitronectin with increasing concentrations of the test compound (10−5–10−12 M) in
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the presence of soluble human αvβ3 integrin. Functionalization of ligand 9 has a negligible effect on
receptor binding (IC50: 0.71 nM vs cilengitide IC50: 0.54 nM) [34]. Despite the increased size and steric
bulkiness, conjugates 10 and 11 retained strong binding affinity to the receptor with IC50 values in the
low nanomolar range (8.3 nM and 12.7 nM, respectively).
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3.3. Plasma Metabolic Stability
Keeping in mind that our conjugates contain moieties susceptible for hydrolysis, and in vivo
payload deactivating metabolism of antibody–cryptophycin conjugates was also reported [50],
the in vitro plasma metabolic stability of cryptophycins and RGD–cryptophycin conjugates was
assayed in human and mouse plasma.
Plasma metabolic stability studies demonstrated that our selected payload (cryptophycin-55
glycinate, 4) shows markedly improved stability compared to the parent compound (cryptophycin-52,
2) in murine plasma and a good stability in human plasma over 24 h (Figure S1A,B). Cryptophycin-52
demonstrated significant metabolism in mouse plasma, including hydrolysis of the macrocycle and loss
of units C and D (Figure S1C,D). The same metabolic pathway was proposed for an epoxide containing
cryptophycin analog used as ADC payload [50]. In contrast, esterification of the chlorohydrin
derivative with glycine was found to provide an enhanced protection of the macrocycle. Taking
into account, that cryptophycin-55 glycinate was not affected by ester or amide hydrolysis, increases
its potential to be an effective payload.
Conjugates 10 and 11 display good stability in human plasma, with half-lives of more than 24 h
and 20 h, respectively (Figure 2B,C). Interestingly, stability in mouse plasma was influenced by the type
of self-immolative moiety, conjugate 11 containing the peptide-based Val-Cit-Gly-Pro linker displayed
superior stability (t1/2 = 23 h) compared to conjugate 10 with the Val-Cit-PABC linker (t1/2 = 6 h).
Metabolite identification revealed that the most relevant biotransformation, responsible for the lack of
stability of conjugate 10 in mouse plasma, is the hydrolysis of the Val-Cit-PABC linker, resulting in the
release of cryptophycin-55 glycinate as major metabolite (Figure 2D). The amide bond between the Cit
and the PABC self-immolative moiety is known to be susceptible to enzymatic hydrolysis in mouse
plasma [51]. Full metabolite analysis revealed additional minor metabolites of conjugate 10 in mouse
plasma (Table S1, Figure S2).
Our results are consistent with previously published data, showing good stability of
Val-Cit-PABC-containing conjugates in human plasma [45] and comparable mouse serum stability
of SMDCs bearing the same linker [52]. Furthermore, conjugate 11 containing the Val-Cit-Gly-Pro
peptidic linker has similar plasma stability as an octreotide–cryptophycin conjugate having the same
linker [26].
3.4. Drug Release by Cathepsin B and Degradation in Human Liver Lysosomes
To confirm the susceptibility of the bioconjugates to enzymatic cleavage and prove efficient
drug release, the cleavage of conjugates 10 and 11 was monitored in the presence of cathepsin B
(1 U/mL) at 37 ◦C. As expected, conjugates 10 and 11 were rapidly cleaved upon incubation with
the enzyme (Figure 3B). In case of conjugate 10, the enzymatic cleavage of Val-Cit linker resulted
in 1,6-elimination of the PABC-spacer and the release of the highly active payload cryptophycin-55
glycinate (4) was observed within 15 min following incubation. These results are in agreement
with previously reported studies of enzymatic drug release from SMDCs and ADCs containing the
Val-Cit-PABC linker [45,53]. In contrast, the cathepsin B mediated linker cleavage of conjugate 11 led
to the formation of Gly-Pro-Cry-55gly (12), which was not further metabolized to cryptophycin-55
glycinate under the test conditions. This indicates that the enzymatic activation is not followed by
intramolecular cyclization and self-immolation of the Gly-Pro dipeptide (Figure 3A).
Although it was reported that prodrugs that contain the Gly-Pro dipeptide linked to paclitaxel via
ester bond are able to efficiently release paclitaxel after incubation with plasmin for 3 h [54], our results
indicate that self-immolation by diketopiperazine formation does not take place when the Gly-Pro
dipeptide is connected to the drug via amide bond. However, the cytotoxicity of metabolite 12 is still
of high relevance for the biological activity of conjugate 11.
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Figure 3. (A) Cleavage and self-immolation mechanism of conjugates 10 and 11 in the presence of
cathepsin B enzyme. (B) Cleavage and metabolism of conjugate 10 (left) and 11 (right) upon incubation
with cathepsin B enzyme.
I a similar experiment, incubation of conjugates 10 and 11 with human liver lysosomes confirmed
the above presented metabolic pathway for each conjugate. Cryptophycin-55 glycinate was found
to be released in the case of conjugate 10, while the formation of Gly-Pro-Cry-55gly metabolite was
characteristic for conjugate 11, without further self-immolation step (Figures S3 and S4). Control
experiments indicated that both conjugates are stable in the absence of enzyme or lysosomes. These
experiments demonstrated efficient linker processing in the presence of cathepsin B and in the
intracellular compartment. Additionally, the character of self-immolative spacer resulted in different
drug release profiles.
3.5. In Vitro Cytotoxicity Assay
Having determined that the self-immolative moiety has a great impact on the intracellular
activation of the RGD–cryptophycin conjugates, an MTT-based cell viability assay was used to evaluate
the in vitro cyto oxic ty of the payload 4, the drug-containing metabolite 12, and conjuga es 10 and
11 (T ble 1, Figure 4). The M21 and M21-L human melanoma cells were used to test in vitro the
tumor- arg t g potential of the novel conjugates [55,56]. The M21 cells overexpress αvβ3 integrin,
while the M21-L, a stable variant of the wild type cell line, fails to express integrin αv, thus causing a
lack of αv integr heterod mers (αvβ3, αvβ5, and αvβ6). The integrin αv and αvβ3 expression was
confirmed by flow cytometry alysis (Figure S5).
Cryptophycin-55 glycinate displayed high in vitro potency against both cell lines with IC50 value
in the sub nanomolar range. However, the parent compound, cryptophycin-52, showed a 10-20-fold
higher biol gical activity usi g the ame cell l nes and est c nditions (IC50 = 0.07 nM a d 0.02 nM in
M21 and M21-L cells, respectively). Furth rmore, the Gly-Pro-Cry-55gly (12) metabolite was similarly
active as the free payload, suggesti at inefficient drug rel ase does not compromise biological
activity. These data demon trate that esterifica ion of the chlorohydrin with l cine or Gly-Pro-Gly
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tripeptide may result only in a slightly decreased potency compared to cryptophycin-52, likely due to
different membrane permeability or lower tubulin binding affinity of these derivatives.
Table 1. Cytotoxic potencies of cryptophycin-55 glycinate (4), drug-containing metabolite 12, and
bioconjugates 10 and 11 against M21 and M21-L human melanoma cells.
Entry Compound
IC50 (nM)
M21 (αvβ3+) M21-L (αv-, αvβ3-)
1 Cry-55gly (4) 0.75 ± 0.11 0.14 ± 0.08
2 Gly-Pro-Cry-55gly (12) 0.15 ± 0.03 0.039 ± 0.01
3 c(RGDfK)-Val-Cit-PABC-Cry-55gly (10) 7.63 ± 0.76 5.80 ± 4.30
4 c(RGDfK)-Val-Cit-Gly-Pro-Cry-55gly (11) 0.16 ± 0.02 0.15 ± 0.02
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Figure 4. Cytotoxic effect of unconjugated cryptophycin-55 glycinate (4), conjugates 10, 11, and
etabolite 12 against 21 and 21-L hu an elano a cells after 72 h (2 h treat ent and additional
70 h incubation). Curves obtained by non-linear regression (four-parameter dose-response, error bars
represent the standard deviation of triplicates, the measurements were repeated twice).
Both conjugates are highly potent; the determined IC50 values are within a range of 0.15–7.63 nM.
Conjugate 10 containing the Val-Cit-PABC linker shows slightly reduced activity compared to
cryptophycin-55 glycinate, while conjugate 11 bearing the Val-Cit-Gly-Pro linker shows equal potency
to that of metabolite 12. Moreover, conjugate 11 was ~300-fold more potent compared to the
model compound azido-functionalized cryptophycin-RGD conjugate [18], verifying the potential
of cryptophycin-based conjugates containing cleavable linkers.
Both conjugates exhibit similar cytotoxicity against the antigen-positive and antigen-negative
cell line, indicating that there is no apparent correlation between the integrin αv/αvβ3 expression
level and the observed in vitro potency. It has been shown, similarly, that cytotoxicity of the RGD
peptidomimetic-α–amanitin conjugates was not integrin-specific when tested on human glioblastoma
U-87 (αvβ3+) and breast adenocarcinoma MDA-MB-468 (αvβ3-) cells, and it was then proposed that
the internalization process was mediated by integrins different from αvβ3 (e.g., αvβ5) [57]. To better
understand these findings, confocal microscopy studies were performed to investigate the delivery
and uptake of RGD-conjugates in M21 and M21-L human melanoma cells.
3.6. Intracellular Uptake Studies
To explore cell surface binding and delivery of RGD conjugates, two analogous conjugates
were synthetized, in which the cytotoxic payload was replaced with the infrared dye, cyanine5.5.
Self-immolative linkers 5 and 6 were reacted with the Cy5.5 amine in good yields giving compounds
13 and 14 (Scheme S4). Fluorescently labeled conjugates 15 and 16 were obtained in satisfactory yields
and excellent purity by CuAAC click reaction with the azido-functionalized RGD-ligand 9. Confocal
microscopy studies were carried out with living M21 and M21-L cells. Similar binding and intracellular
uptake could be observed for the two fluorescently labeled compounds in both cell lines after a period
of 30 min (Figure S6). The intracellular uptake of compounds 15 and 16 in the M21-L cells indicates
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that internalization of these is mediated by a process independent of αv-integrin. The results, applying
constructs of c(RGDfK)-linker-fluorescent dye, are consistent with previous reports showing that
endocytosis of cyclo-RGD peptides is integrin independent and follows a fluid phase uptake [58]. In a
different study, an αvβ3-independent uptake was confirmed for the monomeric RGD-peptide, while
the multimeric RAFT-RGD-Cy5 was efficiently internalized with integrin αvβ3 via clathrin-mediated
endocytosis [59]. All these findings support the explanation that a non-integrin-mediated uptake of
the cryptophycin-conjugates 10 and 11 can be accounted for the observed in vitro potencies.
Apart from the involvement of the targeting RGD-ligand for the internalization of the SMDCs,
the high hydrophobicity of the cytotoxic payload may significantly accelerate the uptake of the
RGD–cryptophycin conjugates, and thus compromise the in vitro selectivity. In fact, it was shown
that the uptake of 3H-cryptophycin-52 by THP-1 and H-125 cells was rapid, reaching a plateau
within 20 min, and irreversible, as no dissociation or efflux from the cells was observed [60]. In a
separate experiment, 3H-cryptophycin-52 became 730-fold more concentrated in HeLa cells upon
20 h incubation [61]. Although the short treatment time in the cytotoxicity assay aimed to minimize
such undesired interactions, a nonspecific endocytic process mediated by the hydrophobic payload,
that promotes internalization of the conjugates in the antigen-negative cells, cannot be excluded.
4. Conclusions
In summary, we have described the synthesis of two novel integrin-targeted SMDCs based on
the conjugation of the highly potent cytotoxic payload, cryptophycin-55 glycinate, to the c(RGDfK)
integrin ligand through the protease sensible Val-Cit dipeptide linker combined with the PABC
or Gly-Pro self-immolative moieties. First, it was shown that our selected payload is remarkably
more stable in mouse plasma compared to the parent compound, cryptophycin-52, and it is not
affected by ester or amide hydrolysis. The exceptional stability of cryptophycin-55 glycinate verifies
its development as SMDC payload. Secondly, it was found that the biological and biochemical
properties of the conjugates strongly depend on the linker type. On one hand, conjugate 10 bearing
the Val-Cit-PABC linker exhibited satisfactory stability in mouse plasma, and it was highly stable in
human plasma. Furthermore, its linker was efficiently cleaved in the presence of cathepsin B releasing
free cryptophycin-55 glycinate. The conjugate displayed high in vitro potency against M21 and M21-L
human melanoma cells with IC50 values in the low nanomolar range. On the other hand, conjugate 11
with the Val-Cit-Gly-Pro peptide linker showed excellent stability both in mouse and human plasma.
Enzymatic linker cleavage resulted in the release of the Gly-Pro-Cry-55gly (12) metabolite, indicating
the lack of an efficient self-immolation step. Despite the inefficient release of the free drug, conjugate
11 showed enhanced potency compared to conjugate 10, with IC50 values in the sub nanomolar range.
Finally, the excellent in vitro activity of the novel bioconjugates was accompanied with inferior
selectivity for cell lines with different integrin αvβ3 expression level. These results indicate that the
RGD–cryptophycin conjugates are internalized by a nonspecific process, which can be attributed both
to the RGD ligand and the high hydrophobicity of the payload and/or conjugates. In the light of these
results, further opportunities arise for the design of novel cryptophycin-based therapeutic agents with
improved tumor selectivity.
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